In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat

Eur J Pharmacol. 1997 Jan 14;319(1):1-4. doi: 10.1016/s0014-2999(96)00922-3.


The beta-amyloid peptide-(25-35) fragment, but not beta-amyloid peptide-(1-28), shares with beta-amyloid protein-(1-42) the ability to self-aggregate and to induce neurotoxicity in vitro. This study examined the induction of amnesia in rats given intracerebroventricularly soluble or aggregated beta-amyloid peptide-(25-35) (5-45 nmol), or beta-amyloid peptide-(1-28) (15 nmol). Memory deficit in the water-maze test, examined 14 days after aggregated beta-amyloid peptide-(25-35) injection, was more pronounced than with soluble beta-amyloid peptide-(25-35). beta-Amyloid peptide-(1-28) only affected retention. These results confirm the direct amnesic properties of beta-amyloid peptides in the rat brain and showed that prior peptide aggregation markedly facilitates the appearance of amnesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amnesia / chemically induced*
  • Amyloid beta-Peptides / chemistry
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Injections, Intraventricular
  • Male
  • Maze Learning / drug effects
  • Peptide Fragments / chemistry
  • Peptide Fragments / toxicity*
  • Rats
  • Rats, Wistar


  • Amyloid beta-Peptides
  • Peptide Fragments
  • amyloid beta-protein (25-35)